Larvol Delta - A-Two-Part-Doseescalation-Safety-and-Efficacy-Study-of-CID103-in-Adults-With-Active-and-Chronic-Active-Renal-Allograft-Antibody-Mediated-Rejection-ABMR

CID-103 - CASI, Precision Autoimmune Therap

http://clinicaltrials.gov/ct2/show/NCT07641426

Jul 23, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next